BibTex RIS Cite

Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri

Year 2008, Volume: 39 Issue: 1, 27 - 32, 20.07.2014

Yusuf Erzin Aykut F. Çelik Belma Karatoka Mustafa Aslan Bekir Kocazeybek

Keywords

İnflamatuar barsak hastalığı PAB GAB

References

  • 1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599-603.
  • 2. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665.
  • 3. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170 (Suppl.): 2-6.
  • 4. Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13. 5. Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 2000; 47: 44-48.
  • 6. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249- 266.
  • 7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86.
  • 8. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-976. Cerrahpafla T›p Derg 2008; 39(1): 27-32
  • 9. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
  • 10. Quinton JF, Sendid B, Reumaux D, et al. AntiSaccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-91.
  • 11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734.
  • 12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-7.
  • 13. Fricke H, Birkhofer A, Folwaczny C, Mesiter W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn’s disease. Eur J Clin Invest 1999; 29: 41-45.
  • 14. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997; 40: 481-484.
  • 15. Seibold F, Weber P, Jenss H, Wiedmann KH 9. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
  • 10. Quinton JF, Sendid B, Reumaux D, et al. AntiSaccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-91.
  • 11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734.
  • 12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-7.
  • 13. Fricke H, Birkhofer A, Folwaczny C, Mesiter W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn’s disease. Eur J Clin Invest 1999; 29: 41-45.
  • 14. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997; 40: 481-484.
  • 15. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991; 32: 1192-7.
  • 16. Klebl FH, Bataille F, Huy C, et al. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 2005; 17: 73-77.
  • 17. Koutroubakis IE, Drygiannakis D, Karmiris K, et al. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci 2005; 50: 2330-2334.
  • 18. Lawrance IC, Hall A, Leong R, et al. comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005; 11: 890-897.
  • 19. Folwaczny C, Noehl N, Tschöp K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997; 113: 101-106.
  • 20. Hibi T, Ohara M, Kobayashi K, et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 1994; 35: 224-230.

Year 2008, Volume: 39 Issue: 1, 27 - 32, 20.07.2014

Yusuf Erzin Aykut F. Çelik Belma Karatoka Mustafa Aslan Bekir Kocazeybek

References

  • 1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599-603.
  • 2. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665.
  • 3. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170 (Suppl.): 2-6.
  • 4. Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13. 5. Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 2000; 47: 44-48.
  • 6. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249- 266.
  • 7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86.
  • 8. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-976. Cerrahpafla T›p Derg 2008; 39(1): 27-32
  • 9. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
  • 10. Quinton JF, Sendid B, Reumaux D, et al. AntiSaccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-91.
  • 11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734.
  • 12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-7.
  • 13. Fricke H, Birkhofer A, Folwaczny C, Mesiter W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn’s disease. Eur J Clin Invest 1999; 29: 41-45.
  • 14. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997; 40: 481-484.
  • 15. Seibold F, Weber P, Jenss H, Wiedmann KH 9. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
  • 10. Quinton JF, Sendid B, Reumaux D, et al. AntiSaccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-91.
  • 11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734.
  • 12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-7.
  • 13. Fricke H, Birkhofer A, Folwaczny C, Mesiter W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn’s disease. Eur J Clin Invest 1999; 29: 41-45.
  • 14. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997; 40: 481-484.
  • 15. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991; 32: 1192-7.
  • 16. Klebl FH, Bataille F, Huy C, et al. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 2005; 17: 73-77.
  • 17. Koutroubakis IE, Drygiannakis D, Karmiris K, et al. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci 2005; 50: 2330-2334.
  • 18. Lawrance IC, Hall A, Leong R, et al. comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005; 11: 890-897.
  • 19. Folwaczny C, Noehl N, Tschöp K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997; 113: 101-106.
  • 20. Hibi T, Ohara M, Kobayashi K, et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 1994; 35: 224-230.
There are 25 citations in total.

Details

Primary Language Turkish
Journal Section Araştırmalar
Authors

Yusuf Erzin This is me

Aykut F. Çelik This is me

Belma Karatoka This is me

Mustafa Aslan This is me

Bekir Kocazeybek This is me

Publication Date July 20, 2014
Published in Issue Year 2008 Volume: 39 Issue: 1

Cite

APA Erzin, Y., Çelik, A. F., Karatoka, B., Aslan, M., et al. (2014). Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri. Cerrahpaşa Tıp Dergisi, 39(1), 27-32.
AMA Erzin Y, Çelik AF, Karatoka B, Aslan M, Kocazeybek B. Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri. Cerrahpaşa Tıp Dergisi. July 2014;39(1):27-32.
Chicago Erzin, Yusuf, Aykut F. Çelik, Belma Karatoka, Mustafa Aslan, and Bekir Kocazeybek. “Plazma Goblet Hücre Ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı Ve Ülseratif Kolit Ayırımındaki Klinik Değeri”. Cerrahpaşa Tıp Dergisi 39, no. 1 (July 2014): 27-32.
EndNote Erzin Y, Çelik AF, Karatoka B, Aslan M, Kocazeybek B (July 1, 2014) Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri. Cerrahpaşa Tıp Dergisi 39 1 27–32.
IEEE Y. Erzin, A. F. Çelik, B. Karatoka, M. Aslan, and B. Kocazeybek, “Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri”, Cerrahpaşa Tıp Dergisi, vol. 39, no. 1, pp. 27–32, 2014.
ISNAD Erzin, Yusuf et al. “Plazma Goblet Hücre Ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı Ve Ülseratif Kolit Ayırımındaki Klinik Değeri”. Cerrahpaşa Tıp Dergisi 39/1 (July 2014), 27-32.
JAMA Erzin Y, Çelik AF, Karatoka B, Aslan M, Kocazeybek B. Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri. Cerrahpaşa Tıp Dergisi. 2014;39:27–32.
MLA Erzin, Yusuf et al. “Plazma Goblet Hücre Ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı Ve Ülseratif Kolit Ayırımındaki Klinik Değeri”. Cerrahpaşa Tıp Dergisi, vol. 39, no. 1, 2014, pp. 27-32.
Vancouver Erzin Y, Çelik AF, Karatoka B, Aslan M, Kocazeybek B. Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri. Cerrahpaşa Tıp Dergisi. 2014;39(1):27-32.